Fresenius faces massive charges from probe into US business
This article was originally published in Clinica
Executive Summary
Dialysis company Fresenius Medical Care faces a "substantial and material charge" - between $200 million and $500 million by some estimates - in its third quarter, as the company settles investigations by the US government into business practices at its subsidiary National Medical Care (NMC).
You may also be interested in...
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.